• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response†‡

  1. Roeland Zoutendijk1,
  2. Jurriën G. P. Reijnders1,
  3. Ashley Brown2,
  4. Fabien Zoulim3,
  5. David Mutimer4,
  6. Katja Deterding5,
  7. Jörg Petersen6,
  8. Wolf Peter Hofmann7,
  9. Maria Buti8,
  10. Teresa Santantonio9,
  11. Florian van Bömmel10,
  12. Pierre Pradat3,
  13. Ye Oo4,
  14. Marc Luetgehetmann11,
  15. Thomas Berg10,
  16. Bettina E. Hansen1,
  17. Heiner Wedemeyer5,
  18. Harry L. A. Janssen1,§,*,
  19. for the VIRGIL Surveillance Study Group

Article first published online: 25 JUL 2011

DOI: 10.1002/hep.24406

Issue

Hepatology

Hepatology

Volume 54, Issue 2, pages 443–451, August 2011

Additional Information

How to Cite

Zoutendijk, R., Reijnders, J. G. P., Brown, A., Zoulim, F., Mutimer, D., Deterding, K., Petersen, J., Peter Hofmann, W., Buti, M., Santantonio, T., van Bömmel, F., Pradat, P., Oo, Y., Luetgehetmann, M., Berg, T., Hansen, B. E., Wedemeyer, H., Janssen, H. L. A. and for the VIRGIL Surveillance Study Group (2011), Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology, 54: 443–451. doi: 10.1002/hep.24406

Author Information

  1. 1

    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands

  2. 2

    Department of Hepatology and Gastroenterology, Imperial College London, London, United Kingdom

  3. 3

    Department of Hepatology, Hotel Dieu Hospital Lyon, Lyon, France

  4. 4

    Department of Hepatology and Gastroenterology, Queen Elizabeth Hospital, Birmingham, United Kingdom

  5. 5

    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany

  6. 6

    Liver Unit, IFI Institute, Asklepios Klinik St. Georg, Hamburg, Germany

  7. 7

    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany

  8. 8

    Department of Hepatology, Hospital Vall de Hebron, Barcelona, Spain

  9. 9

    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy

  10. 10

    Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany

  11. 11

    Department for Internal Medicine, University Medical Center, Hamburg-Eppendorf, Germany

  1. §

    fax: +31 (0)-10-436-5916

*Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, 's Gravendijkwal 230, room Ha 204, 3015 CE Rotterdam, Netherlands

  1. †

    Potential conflict of interest: Jurrien Reijnders has received speaker's honoraria from Novartis and Bristol-Myers Squibb. Fabien Zoulim is consultant for Bristol-Myers Squibb, Gilead, Roche, and Novartis. David Mutimer has received honoraria and grants from Bristol-Myers Squibb. Jörg Petersen is a consultant for Bristol-Myers Squibb and received research support. Maria Buti has received speaker's honoraria and an advisory board fee from Bristol-Myers Squibb. Florian van Bommel has received travel grants from Roche and Gilead. Thomas Berg is a consultant for, advises, is on the speakers' bureau of, and has received grants from Gilead, Roche, Novartis, Merck, Tibotec, and Vertex. Heiner Wedemeyer received research grants and speaker's honoraria from Bristol-Myers Squibb, Gilead, Roche, and Novartis. Harry Janssen received grants from and is a consultant for Bristol-Myers Squibb, Gilead Sciences, Novartis, Roche, and Merck.

  2. ‡

    Supported by the Foundation for Liver and Gastrointestinal Research Rotterdam. The study was conducted with support from the European Network of Excellence for Vigilance against Viral Resistance and a research grant from Bristol-Myers Squibb. (Bristol-Myers Squibb was not involved in data collection, data analysis, writing of the manuscript, or decision to publish.)

  3. §

    fax: +31 (0)-10-436-5916

Publication History

  1. Issue published online: 25 JUL 2011
  2. Article first published online: 25 JUL 2011
  3. Accepted manuscript online: 11 MAY 2011 01:38PM EST
  4. Manuscript Accepted: 24 APR 2011
  5. Manuscript Received: 11 FEB 2011
Corrected by:

Correction: Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

Vol. 54, Issue 6, 2281–2282, Article first published online: 30 NOV 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (315K)

References

View Full Article (HTML) Get PDF (315K)